Lead Product(s) : Apabetalone,Atorvastatin,Rosuvastatin Calcium
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apabetalone (RVX000222), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease p...
Product Name : RVX-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Apabetalone,Atorvastatin,Rosuvastatin Calcium
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : For the first time in patients with a recent Acute Coronary Syndrome with diabetes and stage 3 CKD co-morbidities, we observed a 50% reduction of MACE by a medication, apabetalone treatment.
Product Name : RVX-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2020
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
Details : The FDA has accepted Resverlogix BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions.
Product Name : RVX-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apabetalone recently completed the first ever Phase 3 clinical trial of a BET inhibitor for a cardiovascular disease indication.
Product Name : RVX-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2020
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apabetalone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Resverlogix Receives FDA Breakthrough Therapy for Apabetalone
Details : FDA has granted Breakthrough Therapy Designation for apabetalone in combination with high-intensity statins, for the secondary prevention of MACE in patients with type 2 DM and recent ACS.
Product Name : RVX-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2020
Lead Product(s) : Apabetalone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable